Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17210286 | 1.00 | MKNK1 (0.50) | MKNK1IRAK4RXFP1ALDH1A1MAPT | |
| SCHEMBL15862772 | 0.90 | IRAK4 (0.48) | MKNK1IRAK4MAPT | |
| SCHEMBL15862770 | 0.90 | IRAK4 (0.48) | MKNK1IRAK4MAPT | |
| SCHEMBL15862660 | 0.88 | MAPT (0.49) | MKNK1IRAK4MAPT | |
| SCHEMBL15862658 | 0.88 | MAPT (0.49) | MKNK1IRAK4MAPT | |
| SCHEMBL15862477 | 0.88 | IRAK4 (0.48) | IRAK4ALDH1A1MAPT | |
| SCHEMBL15862850 | 0.86 | IRAK4 (0.48) | IRAK4MAPT | |
| SCHEMBL15868368 | 0.86 | IRAK4 (0.48) | IRAK4MAPT | |
| SCHEMBL15862598 | 0.85 | IRAK4 (0.51) | IRAK4 | |
| SCHEMBL15862596 | 0.85 | IRAK4 (0.51) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751892-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751892-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160068543-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068543-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9175007-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9175007-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2014110114-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194417-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194417-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194417-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MKNK1 401/4885IRAK4 4/4885RXFP1 3776/4885 |
| US-20160068543-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MKNK1 401/4885IRAK4 4/4885RXFP1 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.